Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH (MT-06)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03395522
Recruitment Status : Recruiting
First Posted : January 10, 2018
Last Update Posted : December 4, 2019
Sponsor:
Information provided by (Responsible Party):
Medi-Tate Ltd.

Brief Summary:

A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study.

Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.


Condition or disease Intervention/treatment Phase
BPH Device: iTind Not Applicable

Detailed Description:

Primary Study Objective:

The study's primary objective is to assess the efficacy of the Medi-Tate iTind in subjects with symptomatic BPH by reduction of IPSS) (International Prostate Symptoms Score) score.

Secondary Study Objectives:

  • To further evaluate the efficacy of Medi-Tate iTind as determined by increase of maximal urinary peak flow, satisfaction from the device and procedures, sex performance capabilities and ejaculation.
  • Safety will be assessed by the rate of complications attributed to the Medi-Tate iTind and its implantation/retrieval procedures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: device group only
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)
Actual Study Start Date : March 15, 2018
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Device
ITind device implant
Device: iTind
device implanted for 5-7 days




Primary Outcome Measures :
  1. IPSS (International Prostate Symptoms Score) Responders Rate [ Time Frame: at Month 6 Visit ]
    the Proportion (%) of Total IPSS Responders (3 points) Rate


Secondary Outcome Measures :
  1. Total IPSS (International Prostate Symptoms Score) Score at [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total IPSS Score

  2. Total IPSS(International Prostate Symptoms Score) Urinary Symptoms Score [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total IPSS Urinary Symptoms Score

  3. Total SHIM (Sexual Health Inventory for Men ) Score [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total SHIM Score

  4. Total ISI (Incontinence Severity Index ) Score [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total ISI Score

  5. Total EJ-MSHQ ( Ejaculation- Male Sexual Health questionnaire) Score [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total EJ-MSHQ Score

  6. Total Flow [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total Flow

  7. Total residual urine [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total residual urine

  8. Total Satisfaction Rate [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in Total Satisfaction Rate

  9. IPSS QoL (Quality Of Life) score [ Time Frame: 6 months ]
    Change from Baseline to Month 6 in IPSS QoL score

  10. Recovery Success Rate [ Time Frame: 1 month ]
    Quality of Recovery Success Rate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male with symptomatic BPH
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject signed informed consent prior to the performance of any study procedures.
  • Male with symptomatic BPH: IPSS symptom severity score ≥ 10.
  • Peak urinary flow of < 12 ml/sec at flowmetry.
  • Prostate volume (as assessed by TRUS) < 120 mL
  • Un-tolerated retrograde ejaculation (alfa-blockers side-effect)
  • Marion's disease (w/o)
  • Subject that is able to complete the study protocol
  • Normal Urinalysis and urine culture.

Exclusion Criteria:

  • Previous prostate surgery
  • Prostate cancer
  • Urethral stricture
  • Bladder stones
  • UTI
  • Obstructing median lobe ≥ 1.2 cm
  • Neurological conditions potentially affecting voiding function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03395522


Contacts
Layout table for location contacts
Contact: Lihi Liviatan 972543114797 lihi@medi-tate.com

Locations
Layout table for location information
Austria
AKH Vienna Not yet recruiting
Vienna, Austria
Contact: Carmen Pozo       carmen.pozosalido@meduniwien.ac.at   
Contact: Veronika Auner-Moser    +43-1-40400-54780    veronika.auner-moser@meduniwien.ac.at   
Austrian Hanusch Hospital Not yet recruiting
Vienna, Austria
Contact: Mathias Tischler       mathias.tischler@wgkk.at   
France
Hôpital Cochin Not yet recruiting
Paris, France
Contact: Nicolas Barry Delongchamps, Prof         
Hôpital Privé des Côtes d'Armor Not yet recruiting
Plérin, France
Contact: Emmanuel Della Negra       negra.emmanuel@wanadoo.fr   
Germany
University Hospital Frankfurt Recruiting
Frankfurt, Germany
Contact: Andreas Becker       Andreas.Becker@kgu.de   
Contact: Anke Strebel    +4969/6301-84778    Anke.Strebel@kgu.de   
Medical center - University of Freiburg Not yet recruiting
Freiburg, Germany
Contact: Martin Schönthaler       martin.schoenthaler@uniklinik-freiburg.de   
Contact: Oksana Ermantraut    +4976127077102    oksana.ermantraut@uniklinik-freiburg.de   
Asklepios Klinik Hamburg Not yet recruiting
Hamburg, Germany
Contact: Anke wahlers       an.wahlers@asklepios.com   
Italy
AOU di Catanzaro Active, not recruiting
Catanzaro, Italy
Azienda Ospedaliera Universitaria San Martino Active, not recruiting
Genova, Italy
San'Andrea Hospital Active, not recruiting
Rom, Italy
San Orbessano Active, not recruiting
Turin, Italy
Spain
Clínica CEMTRO Ventisquero la Condesa Active, not recruiting
Madrid, Spain, 42 28035
Switzerland
Spital Thurgau AG Recruiting
Frauenfeld, Switzerland
Contact: Gregor Kadner       gregor.kadner@stgag.ch   
Contact: Alexandra Keller       alexandra.keller@stgag.ch   
Cantonal Hospital St. Gallen Recruiting
Saint Gallen, Switzerland
Contact: Dominik Abt       Dominik.Abt@kssg.ch   
Sponsors and Collaborators
Medi-Tate Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Francesco Porpiglia, MD San Orbessano
Layout table for additonal information
Responsible Party: Medi-Tate Ltd.
ClinicalTrials.gov Identifier: NCT03395522    
Other Study ID Numbers: MT-06
First Posted: January 10, 2018    Key Record Dates
Last Update Posted: December 4, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No